629-93-6Relevant articles and documents
Contra-thermodynamic Olefin Isomerization by Chain-Walking Hydrofunctionalization and Formal Retro-hydrofunctionalization
Hanna, Steven,Butcher, Trevor W.,Hartwig, John F.
supporting information, p. 7129 - 7133 (2019/09/12)
We report a contra-thermodynamic isomerization of internal olefins to terminal olefins driven by redox reactions and formation of Si-F bonds. This process involves chain-walking hydrosilylation of internal olefins and subsequent formal retro-hydrosilylation. The process rests upon the high activities of platinum hydrosilylation catalysts for isomerization of metal alkyl intermediates and a new, metal-free process for the conversion of alkylsilanes to alkenes. By this approach, 1,2-disubstituted and trisubstituted olefins are converted to terminal olefins.
The fluid-mosaic model, homeoviscous adaptation, and ionic liquids: Dramatic lowering of the melting point by side-chain unsaturation
Murray, Samuel M.,O'Brien, Richard A.,Mattson, Kaila M.,Ceccarelli, Christopher,Sykora, Richard E.,West, Kevin N.,Davis Jr., James H.
body text, p. 2755 - 2758 (2010/07/06)
(Figure Presented) Defying conventional wisdom: Ionic liquids (ILs) with long, unsaturated alkyl appendages (see top structure) defy established trends that link long ion-bound alkyl groups to higher melting points. The new ILs are also less viscous than a saturated standard (see bottom structure) at the same temperature. These features parallel those that underpin homeoviscous adaptation in certain organisms and are indirectly supportive of a fluid-mosaiclike nanoscale character.
Anti-cancer nitro- and thia-fatty acids
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions comprising, as an anti-cancer agent: (a) one or more compounds having the formula NO2-A-B, wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 double bonds, and B is (CH2)m(COOH)n in which n is a integer from 0 to 2 and m is an integer from 0 to 2; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; (b) one or more compounds selected from polyunsaturated fatty acids (PUFA's) having a 16 to 26 carbon atom chain and 3 to 16 double bonds, and wherein the PUFA is covalently coupled at the carboxylic acid group to an amino acid selected from glycine and aspartic acid; (c) one or more compounds selected from unsaturated fatty acids having an 18 to 25 carbon atom chain and 1 to 6 double bonds and wherein the fatty acid has one or two beta-oxa, gamma-oxa, beta-thia, gamma-thia substitutions: or (d) one or more compounds having formula (I) wherein A' is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B' is (CH2)J(COOH)k in which j is an integer from 1 to 3 and K is 0 or 1; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; and a pharmaceutically acceptable carrier or diluent.
